Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Status:
Completed
Trial end date:
2008-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of intravitreal injections of Macugen
every 6 weeks for the treatment of macular edema secondary to branch retinal vein occlusion
(BRVO). We hypothesize that macular edema secondary to BRVO is mediated by VEGF 165 and that
chronic suppression of VEGF 165 will successfully treat BRVO related macular edema.